NCT04908514View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 7, 2021

Primary Completion Date

January 21, 2022

Study Completion Date

January 21, 2022

Conditions
Plaque Psoriasis
Interventions
DRUG

ADX-629

ADX-629 administered orally twice daily (BID) for approximately 12 weeks.

Trial Locations (1)

92123

TCR Medical Corporation, San Diego

Sponsors
All Listed Sponsors
lead

Aldeyra Therapeutics, Inc.

INDUSTRY